局所放射線照射を受けた宿主局所免疫能の変化(ICAM-1,LFA-1を中心として)

局部照射后宿主局部免疫能力的变化（以ICAM-1和LFA-1为中心）

• 批准号: 07771472
• 负责人: 西野 宏
• 金额: $ 0.64万
• 依托单位: Jichi Medical University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Encouragement of Young Scientists (A)
• 财政年份: 1995
• 资助国家: 日本
• 起止时间: 1995 至 无数据
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-07771472/
• 关键词: 頭頸部偏平上皮癌; ICAM-1; LFA-1; 照射

【対象症例と検体】症例の内訳は上顎癌7例,上咽頭癌2例,中咽頭癌1例,下咽頭癌1例,舌癌2例,咽頭癌2例で,上顎癌の2例は異なる照射線量において2回生検した。よって対象献体の内訳は上顎癌9検体,上咽頭癌2検体,中咽頭癌1検体,下咽頭癌1検体,舌癌2検体,咽頭癌2検体である。上顎癌では照射線量別に10Gy:4検体,20Gy:4検体,30Gy:1検体で,他は未治療時の検体である。【方法】使用した一次抗体はICAM-1(DAKO),LFA-1(Bender MedSystems),二次抗体はビオチン標識ウサギ抗マウス抗体(DAKO)であり,ABC法(Vectastain Elite ABC Kit)による免疫組織反応を行った。免疫染色態度は一部の細胞に強い発現性が認められる場合や大部分の細胞に発現性が認められる場合を陽性とした。【結果】17検体中ICAM-1陽性は10検体(59%)で,その中でLFA-1陽性リンパ球を認めたのは2検体(20%)であった。ICAM-1陰性検体ではLFA-1陽性リンパ球を認めなかった。咽頭癌,舌癌,咽頭癌の未治療時の8検体ではICAM-1陽性は4検体(50%)で,その中でLFA-1陽性リンパ球を認めたのは1検体(25%)であった。照射を受けた上顎癌9検体中ICAM-1陽性は6検体(67%)で,その中でLFA-1陽性リンパ球を認めたのは1検体(17%)であった。線量別のICAM-1陽性率では10Gy照射4検体中2検体(50%),20Gy照射4検体中3検体(75%),30Gy照射1検体中1検体(100%)であった。ICAM-1陽性6検体中LFA-1陽性リンパ球を認めたのは20Gy照射の1検体(17%)であった。同一症例の照射線量別変化は2症例で検討できた。1例の検体は10Gy,30GyともにICAM-1陽性であったが,他の1例の検体は10Gy時ICAM-1陰性で20Gy時にICAM-1陽性に変化した。しかしいずれの検体もLFA-1陽性リンパ球は認められなかった。【まとめ】ICAM-1陽性癌細胞の組織内に浸潤するLFA-1陽性リンパ球を認めた。照射を受けた癌細胞においてICAM-1の発現性に変化を起こす例を認めた。

There were 7 cases of upper pharynx cancer, 2 cases of upper pharynx carcinoma, 1 case of middle pharynx carcinoma, 1 case of hypopharyngeal carcinoma, 2 cases of tongue carcinoma, 2 cases of pharynx cancer, 2 cases of upper phar The upper body is cancer 9, the upper pharynx is 2, the middle pharynx is 1, the hypopharynx is 1, the tongue is 2, and the pharynx is 2. The radiation dose of the upper cancer was 10Gy:4 body, 20Gy:4 body, 30Gy:1 body, while he was not cured. [methods] the primary antibody ICAM-1 (DAKO), LFA-1 (Bender MedSystems), secondary antibody (DAKO) were used, and the immune tissue was detected by ABC method (Vectastain Elite ABC Kit). Immunostaining showed that most of the cells were in combination with the majority of cells. [results] ICAM-1 was found in 10 cases (59%) and LFA-1 in 17 cases (20%). ICAM-1, LFA-1, sex, ball, etc. Pharynx cancer, tongue cancer, pharynx cancer 8 days after treatment, the ICAM-1 sex 4 body (50%), the LFA-1 gonadotropin globule (25%), the pharynx cancer 1 body (25%). The ICAM-1 sexual bodies (67%) in the cancer 9 bodies were irradiated, and the LFA-1 sexual bodies (17%) were irradiated. Different doses of ICAM-1, 10Gy, 20Gy, 30Gy and 30Gy irradiated 2 bodies (50%), 3 bodies (75%) and 1% of 1 body respectively. In ICAM-1 sexual 6 bodies, LFA-1 sexual bodies were irradiated with 20Gy in 1 body (17%). In the same case, the dose of radiation was different, and in 2 cases, the radiation dose was different in 2 cases. One patient received 10 Gy gamma ICAM-1 with 30Gy radiation, and the other had ICAM-1 transient 20Gy ICAM-1 during 10Gy. I don't know what to do. I don't know. I don't know what to do. [ICAM-1] the tumor cells of ICAM-1 cancer were infiltrated into the tissue of LFA-1 and the tumor cells were identified. Radiation exposure to cancer cells, ICAM-1 cells, sexual reactions, radiation exposure, cancer cells, cancer cells, cancer cells